that could cause
actual results to differ materially from those described in the forward-
looking statements. These risks and uncertainties are contained in the
Corporation's filings with the Securities and Exchange Commission and
include, but are not limited to: information of a preliminary nature that
may be subject to adjustment, potentially not obtaining or delay in
obtaining FDA approval for new products, governmental restrictions on the
sale of certain products, development by competitors of new or superior
products or cheaper products or new technology for the production of
products, the entry into the market of new competitors, market and customer
acceptance and demand for new pharmaceutical products, availability of raw
materials, timing and success of product development and launches,
dependence on few products generating majority of sales, product liability
claims for which the Company may be inadequately insured, and other risks
identified in this report and from time to time in our periodic reports and
registration statements. These forward- looking statements represent our
judgment as of the date of this report. We disclaim, however, any intent or
obligation to update our forward-looking statements.
'/>"/>SOURCE Caraco Pharmaceutical Laboratories, Ltd. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
South Africa Wins landmark case against pharmaceutical giants2.
Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries3.
Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries4.
Setting up a new pharmaceutical industry in India5.
Medicis Pharmaceutical company enters pediatric market 6.
Supply of Radiopharmaceuticals Hampered by Attacks 7.
Pharmaceutical companies are targeting patients8.
FDA approves Watson Pharmaceuticals Oxytrol patch9.
Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart10.
Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib11.
Pharmaceutical industries grant for R&D to be monitored